Meihua Biotech (600873.SH) pre-cut sales. Net profit for the first half year is estimated to be 600 million yuan to 800 million yuan, a year-on-year decrease of 55% to 66%

According to Zhitong Finance App News, Meihua Biotech (600873.SH) announced that the company expects to achieve net profit of 600 million yuan to 800 million yuan in the half year of 2026. Compared with 1,768 billion yuan in the same period last year, it is expected to decrease 970 million yuan to 1,170 million yuan, a decrease of 55% to 66% over the previous year.

During the reporting period, due to multiple factors such as increased industry supply, the prices of the company's main products such as monosodium glutamate, threonine, and lysine declined year on year, leading to a year-on-year decline in the company's overall operating profit. The company will continue to promote production and cost control, accelerate the layout of high-value-added products such as overseas markets and pharmaceutical amino acids, deepen the optimization and upgrading of production capacity structures and processes, and continuously improve operational resilience.